The impact of elexacaftor/tezacaftor/ivacaftor on cystic fibrosis health-related quality of life and decision-making about daily treatment regimens: a mixed methods exploratory study.
Melissa J BasileJennifer PoloKatherine HenthorneJoan DeCelie-GermanaSusan GalvinJanice WangPublished in: Therapeutic advances in chronic disease (2024)
With little long-term data on the impact of reducing non-ETI treatments, participants weighed how they were feeling, treatment efficacy beliefs, and risk tolerance when making treatment decisions.